期刊文献+

羟基喜树碱联合化疗治疗晚期大肠癌近期疗效分析

Efficacy of combined chemotherapy containing hydroxycamptothecine in the treatment of advanced colorectal cancer
下载PDF
导出
摘要 目的观察以羟基喜树碱为主的联合化疗方案治疗晚期大肠癌的近期疗效及毒副反应.方法 HCPT 8~10 mg/m2,静脉滴注,第1~5天;DDP 20 mg/m2,静脉滴注,第1~3天;CF 100 mg/d,静脉滴注,第1~5天;5-Fu 300 mg/m2,静脉滴注,第1~5天,每21~28 d为一周期,2周期为一疗程.结果 39例均可评价疗效,CR 0例,PR 17例,SD 16例,PD 6例.有效率(CR+PR)43.6%,化疗受益率(CR+PR+SD)84.6%.初治有效率为50.0%,化疗受益率90.6%.毒副反应主要为骨髓抑制和消化道反应.结论羟基喜树碱为主的联合化疗疗效高,毒副反应可耐受. Objective To evaluate the efficacy and toxicity of combined chemotherapy containing hydroxycamptothecine(HCPT) in the treatment of advanced colorectal cancer. Methods HCPT 8-10 mg/ m^2 , CF 100 mg/d,5-Fu 300 mg/m^2 , iv infusion dl-5 ,DDP 20 mg/m^2 iv infusion dl-3. The regimen was repeated every 3 or 4 weeks as 1 cycle. One course consisted of two cycles. Results Thirty-nine cases of advanced colorectal carcinoma were evaluated for efficacy. No one achieved CR, 17 PR, 16 SD, and 6 PD. O- verall response rate was 43.6%, benefit rate was 84.6%. In the primary treatment, the RR was 50.0% ,the benefit rate was 90.6%. The main side effects were myelosuppression, nausea, vomiting and diarrhea. Conclusion Combined chemotherapy with HCPT-containing regimen showed higher efficacy and low toxicity.
出处 《中国肿瘤临床与康复》 2005年第6期556-557,共2页 Chinese Journal of Clinical Oncology and Rehabilitation
关键词 结直肠肿瘤/化学疗法 羟基喜树碱 Colorectal neoplasms/chemotherapy Hydroxycamptothecine
  • 相关文献

参考文献5

二级参考文献20

  • 1孟凡虹,包群,熊辛,孟凡樵.人大肠癌体外短期药物敏感性预测研究[J].中华实验外科杂志,1994,11(6):365-366. 被引量:6
  • 2李国栋.拓朴异构酶特性与肿瘤细胞的耐药性[J].河南肿瘤学杂志,1996,9(4):317-319. 被引量:72
  • 3Rowe PM. Camptothecins: new enthusiasm for an old drug.Lancet, 1995,347:892.
  • 4Slichenmyer WJ, Rowinsky EK, Donehower RC, et al.The current status of camptothecin analogues as antitumor agents,J Natl Cancer Inst,1993,85:271.
  • 5Bleiberg H. Colorectal cancer: the challenge, Eut J Cancer,1996,32(A Suppl 5):S2.
  • 6Labianca R, Pessi A, Facendola G, et al. Modulated 5-fluorouracil (5-FU) regimens in advanced colorectal cancer:a critical review of comparative studies. Eur J Cancer,1996,32(A Suppl5):S7.
  • 7Shimada Y, Rougier P, Pitot H. Efficacy of CPT-11(irinotecan) ad a single agent in metastatic colorectal cancer.Eur J Cancer,1996,32(A Suppl3):S13.
  • 8Wiseman LR, Markham A. Irinotecan. A review of its pharma cological properties and clinical efficacy in the management of advanced colorectal cancer.Drugs,1996,52:606.
  • 9Armand JP, Ducreux M, Mahjoubi M, et al. CPT-11 (irinotecan) in the treatment of colorectal cancer. Eur J Cancer,1995,31(A Suppl 3):1283.
  • 10Cunningham D. Current status of colorectal cancer:CPT-11(irinotecan), a therapeutic innovation. Eur J Cancer, 1996,32(A Suppl 3):S1.

共引文献123

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部